STOCKS TELEGRAPH

Tag: BiondVax Pharmaceuticals Ltd.

  • BiondVax Pharmaceuticals Ltd. (BVXV) stock Rebounds on Successful Closing of $9.8M Offering

    BiondVax Pharmaceuticals Ltd. (BVXV) stock Rebounds on Successful Closing of $9.8M Offering

    BiondVax Pharmaceuticals Ltd. (BVXV) shares entered green after the announcement of the successful closing of the $9.8M offering on Wednesday. Previously, the stock was trading in the red, hence, the news caused it to rebound and recover most of its losses of the day.

    During the regular session, the stock saw a fall of 6.83% at its closing value of $2.32 on an average volume. Following the news, the stock recovered most of its losses, reaching up to $2.47 with a 6.47% increase after hours.

    BiondVax Pharmaceuticals Ltd. has a market capitalization of $35.69 million. Currently, the company has 14.33 million shares outstanding in the market.

    BVXV’s Offering and its Close

    The company had announced the underwritten public offering on December 27, along with its pricing. The expected closing date of the offering was December 29, and as per Wednesday’s announcement, it did close on the date.

    BVXV had offered 4,144,068 American Depository Shares (ADSs) at $2.36 per ADS price. Each of the ADS in the offering represented 40 ordinary shares of the company. Moreover, the gross proceeds from the offering were $9.8 million including the successful execution of over-allotment. Further, this amount does not include underwriting discounts and other expenses.

    According to the CEO of BVXV, Amir Reichman, the net proceeds will provide the company with capital for funding the NanoAb program. The company had recently announced a nanosized antibody program under collaboration with Max Planck Institute, for Covid-19.

    In addition, the company will also use some of the net proceeds for general corporate purposes.

    Recent Developments

    On December 27, the company announced the approval of all proposed resolutions at the Annual General Meeting of Shareholders. The meeting was held on December 27, 2021. Moreover, Mr. Jay Green was elected to the company’s board of directors, as Mr. Isaac Devash retired.

    Mr. Green has vast experience in the field including the recent six-year term with GlaxoSmithKline Plc as Senior Vice President Finance and CFO.

    BVXV’s Financial Data

    On November 30, the company declared its financial results for the third quarter of 2021.

    In the third quarter of 2021, the R&D and G&A expenses were NIS 2.0 million (US$0.6 million) and NIS 6.2 million (US$1.9 million). This compares to NIS 12.6 million and NIS 7.3 million respectively, in the Q3 of 2020.

    Moreover, BVXV ended the third quarter of 2021, with cash and cash equivalents of NIS 34.6 million (US$10.7 million).

  • BiondVax Pharmaceuticals Ltd. (BVXV) Stock Dipped in Premarket, Here’s why

    BiondVax Pharmaceuticals Ltd. (BVXV) is a leading pharmaceutical company. It primarily focuses on the development, manufacture and commercialization of novel treatments for prevention of different infectious diseases. One of the leading product candidates of the company is a novel nano sized antibody (NanoAb). Other pipeline products are also in the process of development.

    The price of BVXV stock during the regular trading on December 23, 2021, with a 4.79% drop was $2.78. At last check in the pre market on December 27, 2021, the stock further dropped by 17.63%.

    BVXV: Events and Happenings

    On December 27, 2021, BVXV reported the pricing of underwritten public offering of 3,813,560 shares at a price of $2.36 per share. The gross proceeds reported to the company were $9.0 million. Each share presents 40 ordinary shares of the company.

    On December 22, 2021, BVXV reported about the collaboration with Max Planck Society and the University Medical Center Göttingen, for the development and marketing of novel COVID-19 NanoAbs. Under the broader agreement, NanoAbs could be used for other disease symptoms in the near future. This aspect of NanoAbs reinforce its unique characteristics of binding affinity, high temperature stability and more efficient pathways of administration.

    BVXV: Key Financials

    On November 30, 2021, BVXV reported its financial results for third quarter ended September 30, 2021. Some of the key highlights are as follows

    Total Assets

    The total assets reported by the company for Q3 2021 were $7.9 million as compared to the same period of 2020 when the assets were $11 million.

    Net Income/Loss per Share

    Basic and diluted net loss per share for Q3 2021 was $2.8 million or $0.02 per share against the same period of 2020 when net income was $17.6 million and per basic share it was $0.12 while per diluted share it was $0.10.

    On November 15, 2021, BVXV reported that the top management of the company presented at the 7th Virtual H.C. Wainwright Annual Conference on the same date. On October 19, 2021, BVXV reported about the 5-year strategic research collaboration with the Max Planck Society and the University Medical Center. The contract is determined by the accomplishment of definitive agreements.

    Conclusion

    The BVXV stock showed significant hike i.e., 51% in comparison to the past month. In the premarket session the stock price dropped sharply possibly due to the company’s announcement of $9 million pricing of underwritten offering of shares. The earlier progress shown by the company is reciprocated and the company should think about new policies to attract the investment.

  • BiondVax Pharmaceuticals Ltd. (BVXV) stock falling in Pre-Market today: Here’s why

    Shares of the BiondVax Pharmaceuticals Ltd. (BVXV) stock were falling in the pre-market trading session today on July 28, 2021, after gaining as much as 26.94% at the previous closing. BVXV stock price saw a downtrend of 3.20% to drop at $3.33 a share as of this writing. Let’s understand the reason behind this fall.

    What’s Happening?

    BiondVax Pharmaceuticals Ltd. is a biopharmaceutical stock focused on the prevention of infectious diseases via the development of therapies in Israel. There seems to be no major culprit behind the falling BVXV stock price. No specific news or press release has been announced to justify this bearish sentiment. It seems that the profit takers have stepped in after the BVXV stock price rose as much as $4.04 per share in the last trading session.

    Financial Results of BVXV stock:

    BiondVax stock announced its first-quarter 2021 financial results on June 23, the highlights of which are given below.

    • BiondVax recorded  NIS(New Israel Shekels) 6.7 million in total operating expenses in the first three months of 2021 as compared to NIS 20 million in the same quarter of 2020.
    • Research and development expenses were NIS 2.75 million for the first quarter of 2021, lower than research and development expenses of NIS 19.0 million in the first quarter of 2020.
    • BiondVax generated net proceeds of $12.8 million from the follow on offering on Nasdaq after deducting underwriter discounts and offering related expenses.

    The operating expense which also includes research and development expenses of Q1 2021 were lesser as compared to the same period in 2020 due to the phase 3 clinical trial and related operations expenses in 2020. The trial was ended in the fourth quarter of 2020.

    Balance Sheet of BVXV stock:

    At the end of the first quarter of 2021, BiondVax stock had cash and cash equivalents of NIS 48.6 million, much higher than the NIS 9.4 million at the end of December 2020. This rise is mainly attributed to net proceeds of $12.8 million from the follow on the offering of the stock in February 2021. As of May 12, 2021, the stock reported NIS 46 million cash and cash equivalents.

    Wrap Up:

    After reaching a certain height in the last trade, BVXV stock is now moving back without any official announcement or activity. The follow on offering that happened in February 2021 has strengthened its balance sheet.

  • What changed for these 46 stocks in Pre Market Session?

    What changed for these 46 stocks in Pre Market Session?

    Alterity Therapeutics Limited (ATHE) stock plunged -10.31% to $2.0 in the pre-market trading after the company announced the approval of a US patent for the next generation.

    Cinedigm Corp. (NASDAQ: CIDM) shares are trading down -4.55% at $0.525 at the time of writing after it posted Second Quarter Fiscal 2021 Earnings. The company’s 52-week range was noted as $0.25 to $6.00. Analysts have a consensus price target of $3.50.

    iBio Inc. (IBIO) tumbled over -2.34% at $1.67 in pre-market trading today as the Company revealed fiscal first quarter 2021 Financial results and provides a business update.

    CBAK Energy Technology Inc. (CBAT), an Electrical Equipment & Parts company, dropped about -7.4% at $9.01 in pre-market trading Wednesday.

    Comstock Mining Inc. (LODE) stock moved down -1.96 percent to $1.0 in the pre-market trading as it revealed to Host Earnings Call.

    CureVac N.V. (CVAC) lost over -3.01% at $74.19 in pre-market trading Wednesday 18 November 2020 after the news that the Company has established a European-based network to ramp Up manufacturing of its COVID-19 vaccine candidate, CVnCoV.

    Oncternal Therapeutics Inc. (ONCT) is down more than -24.88% at $3.11 in pre-market hours Wednesday 18 November 2020 as the Company increases previously revealed bought deal to $22.5 million. The stock had dropped over -9.41% to $4.14 in the last trading session.

    Before the trading started on 18 November 2020, New Concept Energy Inc. (GBR) is down -11.38% to reach $1.48 after the firm announced its Q3, 2020 results. It has been trading in a 52-week range of $0.55 to $2.19.

    Polar Power Inc. (POLA) stock plunged -7.25% to $3.07 in the pre-market trading. The most recent rating by ROTH Capital, on November 07, 2017, is at a Neutral.

    Trinity Biotech plc (NASDAQ: TRIB) shares are trading down 0.0% at $2.9 at the time of writing. The company’s 52-week range was noted as $0.56 to $3.35 as the company set to Host an Earnings Call.

    So-Young International Inc. (SY) grew over 4.65% at $13.5 in pre-market trading today as the company said it is going to report its earnings to result on November 25, 2020.

    BioNTech SE (BNTX), a Biotechnology company, rose about 4.22% at $90.6 in pre-market trading Wednesday after the report that Pfizer and BioNTech planned to file as vaccine proves 95% effective.

    Sunworks Inc. (SUNW) stock moved down -4.91 percent to $3.68 in the pre-market trading after the Company revealed that the proposed merger with the Peck Company Holdings, Inc. failed to secure stockholder approval.

    Sundial Growers Inc. (SNDL) lost over -3.04% at $0.2424 in pre-market trading Wednesday 18 November 2020 following the announcement of its third-quarter earnings results.

    Tuniu Corporation (TOUR) is up more than 1.04% at $1.95 in pre-market hours Wednesday 18 November 2020. The stock had dropped over -3.98% to $1.93 in the last trading session.

    Before the trading started on 18 November 2020, Taiwan Semiconductor Manufacturing Company Limited (TSM) is up 3.22% to reach $98.79 following the report that Samsung heats up chip wars with the claim that it can catch TSMC by 2022. It has been trading in a 52-week range of $42.70 to $102.44.

    Hill International Inc. (HIL) stock plunged -5.49% to $1.55 in the pre-market trading as the company said that CEO Raouf Ghali and CFO Todd Weintraub are scheduled to present at the following investor conferences during the month of November.

    Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) shares are trading down -4.77% at $0.5615 at the time of writing after the preliminary results following vaccination of non-human primates with TNX-1800 a live attenuated COVID-19 vaccine candidate engineered to express the SARS-CoV-2 spike protein after vaccination. The company’s 52-week range was noted as $0.39 to $2.46. Analysts have a consensus price target of $4.

    Genius Brands International Inc. (GNUS) tumbled over -3.42% at $1.13 in pre-market trading today after the company revealed strategic takeover of ChizComm Ltd. and ChizComm Beacon Media.

    Medley Management Inc. (MDLY), an Asset Management company, rose about 33.73% at $9.0 in pre-market trading Wednesday announced third-quarter earnings results.

    China SXT Pharmaceuticals Inc. (SXTC) stock moved down -3.59 percent to $0.2603 in the pre-market trading.

    Camtek Ltd. (CAMT) lost over -3.64% at $19.05 in pre-market trading Wednesday 18 November 2020 following the news of the commencement of a proposed underwritten public offering of three million ordinary shares.

    Cellectis S.A. (CLLS) is up more than 5.58% at $20.8 in pre-market hours Wednesday 18 November 2020, after the firm announced the appointment of Kyung Nam-Wortman as Cellectis’ Executive Vice President, Chief Human Resources Officer. The stock had dropped over -1.79% to $19.70 in the last trading session.

    Before the trading started on 18 November 2020, TechnipFMC plc (FTI) is up 4.34% to reach $8.42 after the Company received notice to proceed with the EPC contract for Sempra LNG’s and IEnova’s Energía Costa Azul LNG facility. It has been trading in a 52-week range of $4.49 to $21.84.

    Li Auto Inc. (LI) stock soared 3.17% to $36.16 in the pre-market trading after the Company revealed the 3rd quarter of 2020 Earnings results. The most recent rating by Citigroup, on November 16, 2020, is at a Buy.

    BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) shares are trading down -2.47% at $2.76 at the time of writing. The company’s 52-week range was noted as $2.35 to $62.00.

    Neptune Wellness Solutions Inc. (NEPT) tumbled over -2.63% at $1.85 in pre-market trading today after the company posted 2nd quarter loss and missed the predictions.

    Livent Corporation (LTHM), a Specialty Chemicals company, rose about 4.19% at $15.9 in pre-market trading Wednesday following the report of Analysts revised their forecast after disappointing Earnings.

    Micro Focus International plc (MFGP) stock moved up 29.73 percent to $4.8 in the pre-market trading.

    Houghton Mifflin Harcourt Company (HMHC) gained over 5.63% at $3.0 in pre-market trading Wednesday 18 November 2020 after the Company announced financial results for the quarter ended September 30, 2020. The Company revealed its plan to explore the potential sale of HMH Books & Media, its Consumer Publishing business.

    Acasti Pharma Inc. (ACST) is up more than 3.81% at $0.218 in pre-market hours Wednesday 18 November 2020 as the Company offered a business update for Q2, 2020. The stock had jumped over 0.77% to $0.21 in the last trading session.

    Before the trading started on 18 November 2020, Canaan Inc. (CAN) is up 8.73% to reach $3.61. It has been trading in a 52-week range of $1.76 to $13.00.

    VAALCO Energy Inc. (EGY) stock soared 45.1% to $1.48 in pre-market trading.

    Liminal BioSciences Inc. (NASDAQ: LMNL) shares are trading up 11.37% at $4.31 at the time of writing posted third-quarter results. The company’s 52-week range was noted as $3.51 to $31.45.

    Carver Bancorp Inc. (CARV) grew over 3.89% at $6.95 in pre-market trading today.

    Vaxart Inc. (VXRT), a Biotechnology company, dropped about -2.47% at $5.53 in pre-market trading Wednesday after it publicized that it is set to host a Key Opinion Leader (KOL) panel for investors entitled “An Oral Tablet Vaccine – A Potential Global Solution to COVID-19 and Norovirus?” on Thursday, November 19, 2020, at 12pm Eastern Time.

    SCWorx Corp. (WORX) stock moved down -3.64 percent to $1.06 in the pre-market trading.

    Sunoco LP (SUN) lost over -7.0% at $27.11 in pre-market trading Wednesday 18 November 2020 as the Company gained above 5% as Q3 Earnings topped predictions.

    NIO Limited (NIO) is up more than 3.78% at $48.35 in pre-market hours Wednesday 18 November 2020 as the Company revealed its Q3 loss less than expected, whiles sales topped predictions. The stock had jumped over 2.22% to $46.59 in the last trading session.

    Before the trading started on 18 November 2020, Ocugen Inc. (OCGN) is up 4.27% to reach $0.3029 as Company recently revealed Q3 results. It has been trading in a 52-week range of $0.17 to $0.96.

    Weidai Ltd. (WEI) stock soared 9.4% to $1.63 in the pre-market trading after the report that the Company regained compliance after receipt of NYSE Non-compliance letter regarding ADS trading price on October 20, 2020. The most recent rating by Morgan Stanley, on January 21, 2020, is at an Underweight.

    Magnolia Oil & Gas Corporation (NYSE: MGY) shares are trading up 2.99% at $6.2 at the time of writing after the Company missed Earnings predictions. The company’s 52-week range was noted as $3.23 to $13.28.

    Waitr Holdings Inc. (WTRH) grew over 13.68% at $3.24 in pre-market trading today as the Company beat the Earnings outlook.

    Norwegian Cruise Line Holdings Ltd. (NCLH), a Travel Services company, dropped about -6.17% at $20.7 in pre-market trading Wednesday after the company revealed the pricing of 40,000,000 ordinary shares.

    IZEA Worldwide Inc. (IZEA) stock moved up 5.49 percent to $0.77 in the pre-market trading as it revealed Q3 financial results.

    The Boeing Company (BA) gained over 3.53% at $217.46 in pre-market trading Wednesday 18 November 2020 after the report that Boeing’s 737 Max cleared to fly in the US after crashes.